Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Interest Expense : $-0.28 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coeptis Therapeutics Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Coeptis Therapeutics Holdings's interest expense for the three months ended in Mar. 2024 was $ -0.20 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.28 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Coeptis Therapeutics Holdings's Operating Income for the three months ended in Mar. 2024 was $ -2.92 Mil. Coeptis Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2024 was $ -0.20 Mil. Coeptis Therapeutics Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Coeptis Therapeutics Holdings Interest Expense Historical Data

The historical data trend for Coeptis Therapeutics Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coeptis Therapeutics Holdings Interest Expense Chart

Coeptis Therapeutics Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.15

-0.19

-0.22

-0.11

Coeptis Therapeutics Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial									-0.03	-0.04	-0.02	-0.01	-0.20

Coeptis Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.28 Mil.

Coeptis Therapeutics Holdings (NAS:COEP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Coeptis Therapeutics Holdings's Interest Expense for the three months ended in Mar. 2024 was $-0.20 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-2.92 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.21 Mil.

Coeptis Therapeutics Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Coeptis Therapeutics Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Coeptis Therapeutics Holdings (Coeptis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coeptis Therapeutics Holdings Inc (NAS:COEP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

105 Bradford Road, Suite 420, Wexford, PA, USA, 15090

Website

https://www.coeptistx.com

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio comprises multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Executives

Tara Desilva	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
David Mehalick	director, 10 percent owner, officer: CEO and President	5000 TRESSDALE DRIVE, GIBSONIA PA 15044
Christopher P. Cochran	director	105 BRADFORD RD., SUITE 420, WEXFORD PA 15090
Gene Salkind	director	1165 WRACK ROAD, MEADOWBROOK PA 19046
Daniel Alexander Yerace	director, officer: VP of Operations	402 SCHOMBURG COURT, CRANBERRY TOWNSHIP PA 16066
Chris Calise	director, 10 percent owner, officer: Chief Financial Officer	801 S. POINTE DRIVE SUITE TH-1, MIAMI BEACH FL 33139
Philippe Deschamps	director	105 BRADFORD RD, SUITE 420, WEXFORD PA 15090
Christine Elise Sheehy	officer: CFO and Secretary	206 TAMARACK DRIVE, MARS PA 16046
Harraden Circle Investments, Llc	10 percent owner	299 PARK AVE, 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Lp	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Harraden Circle Investors Gp, Llc	10 percent owner	299 PARK AVE., 21ST FLOOR, NEW YORK NY 10171
Fortmiller Frederick Vincent Jr.	10 percent owner	151 LULL ROAD, NEW BOSTON NH 03070
Harraden Circle Investors, Lp	10 percent owner	299 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10171
Plc Barclays	10 percent owner	1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Paul J Glazer	10 percent owner	250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019